1 / 9

CRO Market Focus Priorities Trials and Race for Excellence in 2020

The impact of COVID-19 has forced many pharmaceutical companies to divert their attention from existing portfolios and work toward infectious disease trials.<br>Read More: https://us.sganalytics.com/whitepapers/cro-market-focus-priorities-trials-and-race-for-excellence-in-2020/

Elsa24
Download Presentation

CRO Market Focus Priorities Trials and Race for Excellence in 2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SGA Whitepaper SGA Whitepaper May 2020 May 2020 AS NEEDS CHANGE CRO MARKET CALIBRATES Changes in focus, priorities, trials and race for excellence in 2020

  2. CONTENTS 1 Introduction: disruptions in the (Contract Research Organization) CRO market 3 2 Key findings of an SG Analytics study on global clinical trials market in 2020 4 3 Final word 8 SGA Whitepaper | May 2020 www.sganalytics.com 2

  3. INTRODUCTION Disruptions in the CRO market The year 2020 started on a promising note with key pharmaceutical companies focusing on oncology as their major trial area. Though the number of oncology trials registered in 2019 and Q1 2020 are high, infectious diseases have taken a second spot replacing major therapeutic areas such as central nervous system (CNS) and cardiology. The impact of COIVD-19 has forced many pharmaceutical companies to divert their attention from existing portfolios and work towards infectious diseases trials. There are new players in the market who are expected to fuel more competition and initiate a race for excellence. Due to adoption of digital technologies, many CROs are expected to manage the situation better than others. The CRO market has witnessed the disruption of monopoly of big players due to COVID-19. Big CRO service providers such as IQVIA reported 80% trial sites being hit due to pandemic (expecting 36% inaccessibility in Q3, 2020) while Icon, another CRO reported 65% test sites getting impacted. Globally CROs have been witnessing site ID and enrollment delays due to “site closures and movement restrictions” on trial participants. On the other hand, some players have gone digital to disrupt and calibrate their existing business model. US based PPD Inc. has switched to digital services considering the expected hurdles due to the pandemic that could impact the design and conduct of clinical studies, particularly the inability of patients to visit research sites. PPD has decided to collaborate with customers, regulatory personnel and industry partners to deploy digital and virtual solutions in the global market. Currently, many big players in the pharmaceutical market have either cancelled or suspended new/or ongoing trials. Pharma companies are also planning judicious spending in H2, 2020, considering the impact of pandemic on global drug sales. At SG Analytics Inc., we conducted a research study in April 2020 to examine the global CRO market in the light of global lockdown caused by the Coronavirus pandemic. The sectors and companies which may remain visible for the rest of the year have been indicated and as per the findings; some of the therapeutic areas which were hot in 2019, have taken a weaker position in the first half of this year (till April 2020). Pharma stakeholders, who are closely watching the developments and disruptions in the CRO market, might find these observations indicative and useful while they plan the second half of 2020. SGA Whitepaper | May 2020 www.sganalytics.com 3 3

  4. KEY OBSERVATIONS OF SGA’S RESEARCH STUDY ON THE GLOBAL CLINICAL TRIALS MARKET SGA Whitepaper | May 2020 www.sganalytics.com 4

  5. OBSERVATION #1 Decrease in number of new trial registrations is observed in all therapy areas in Q1 of 2020 compared to Q1 of 2019 and 2018, except for oncology and infectious diseases. New clinical trials registrations in Q1 of 2018, 2019 and 2020 1000 922 900 841 No. of new trials registered 813 800 700 600 500 378 400 289 286 259 259 257 300 248 250 243 198 181 195 170 165 165 165 164 162 158 200 136 134 118 102 99 90 90 88 85 80 63 100 0 Oncology Cardiovascular Immunological Infectious Diseases Dermatology Metabolic Disorders Respiratory CNS Diseases Musculoskeletal Genetic Disorders Kidney Disease 2018 2019 2020 Please note that the comparison has been made considering only drug/biological intervention trials. Other trials have been excluded from the above analysis. OBSERVATION #2 Other than segments such as oncology and infectious diseases, all therapy areas have shown a downward trend in terms of new trial registrations in Q1 of 2020 compared to Q1 of 2019 and 2018 due to the impact of COVID-19. % Changes in new trials registration in Q1 of 2018, 2019 and 2020 Infectious Diseases Metabolic Disorders Genetic Disorders % Change in new trial registrations Oncology Cardiovascular Immunological Dermatology Respiratory CNS Diseases Musculoskeletal Kidney Disease 60 47.1 50 40 30 20.9 20 15.7 20 12.5 11.6 9.7 9.6 10 4.4 2.8 2.1 1.2 0 -1.0 -1.5 -10 -5.9 -6.1 -6.2 -9.1 -20 -17.6 -23.7 -30 % Change in new trials from 2018 Q1 to 2019 Q1 % Change in new trials from 2019 Q1 to 2020 Q1 SGA Whitepaper | May 2020 www.sganalytics.com 5

  6. OBSERVATION #3 Global players have slowed down when it comes to trial registration in Q1,2020. Is it a wait and watch situation? Or is this part of a new global strategy? No. of new trials 60 No of new trial registrations 52 50 39 39 37 37 40 35 34 32 30 30 28 27 30 26 25 25 23 22 21 21 19 18 20 16 13 13 12 12 12 9 10 5 5 0 Merck & Co., Inc Johnson & Johnson Bayer Astrazeneca Pfizer Novartis Roche Sanofi GlaxoSmithKline Gilead 2018 2019 2020 Please note that the comparison has been made considering only drug/biological intervention trials. Other trials have been excluded from the above analysis. OBSERVATION #4 Though the impact of COVID-19 may have caused a negative trend on the overall global new trial registrations (across therapy areas); oncology is still maintaining its position as the most favored and focused segment when it comes to new trial registrations in Q1 of 2020. No. of new trials in oncology - top pharma companies Oncology 30 940 No of new trial registrations No of new trial registrations 922 25 920 24 24 25 23 900 21 880 20 17 17 16 860 841 15 13 840 12 12 813 10 820 10 8 800 780 5 2 2 760 740 0 Merck & Co., Inc Johnson & Johnson Bayer AstraZeneca Pfizer 2018 2019 2020 2018 2019 2020 Oncology SGA Whitepaper | May 2020 www.sganalytics.com 6

  7. OBSERVATION #5 Due to COVID-19 pandemic, the number of new trial registrations were reported to have decreased and the worst hit segments were respiratory disorders, musculoskeletal disorders, kidney diseases and metabolic disorders. Musculoskeletal Kidney disease 140 90 118 80 120 102 70 100 No of new trials 90 No of new trials 60 80 50 40 60 30 40 20 20 10 0 0 2018 2019 2020 2018 2019 2020 Metabolic disorders Respiratory 185 180 160 180 140 No of new trials No of new trials 175 120 100 170 80 165 60 40 160 20 155 0 2018 2019 2020 2018 2019 2020 Please note that the comparison has been made considering only drug/biological intervention trials. Other trials have been excluded from the above analysis. SGA Whitepaper | May 2020 www.sganalytics.com 7

  8. FINAL WORD While cost cutting is definitely on their minds, some CROs are considering alternative approaches with customers on a case to case basis (study) such as remote and risk-based monitoring and ‘at home’ services delivered through third party clinical research companies. SG Analytics has been tracking the growth of the pharmaceutical companies and CRO market and has been helping industry clients get a real time update on clinical trials, new drug launches, new patent filing and more. CRO OFFERINGS Site identification Clinical trial landscape Expanded access program Life cycle management Launch estimate Biomarkers Risk factors Key Opinion Leaders (KOL) identification Clinical trials tracking Clinical trials profiling Patient pool SGA Whitepaper | May 2020 SGA Whitepaper | May 2020 www.sganalytics.com www.sganalytics.com 8

  9. About the Authors Dr Siddhartha Dutta Practice Head – Healthcare Dr Siddhartha Dutta is the Practice Head, Healthcare at SG Analytics. He has been working in the medical industry for more than 21 years. Dr. Dutta has been credited with numerous business articles on healthcare technology, CRO, pharmaceutical trends and more. He has more than 7 international publications, patents to his credit and is currently one of the panelists in the review committee of an international journal (scientific) besides being a scientific advisor and board member to a global healthcare company. Praveen Kumar Bandaru Senior Research Analyst Praveen Kumar Bandaru is a Senior Research Analyst in SG Analytics (Pune). He has hands on experience in clinical trial registries, PubMed, scientific conferences and global regulatory registries like USFDA, EMA etc. He has conducted primary and secondary market research for both drugs and devices. He has also managed the collection of data from clinical trial registries, scientific conferences and various other company sources. Sharing Insights Watch and enjoy our corporate videos THE CEO SPEAK: Success Mantra of a Research & Analytics Firm Click on the above title to watch the video RESEARCH | ANALYTICS | TECHNOLOGY New York | Seattle | London | Zürich | Pune | Hyderabad About SG Analytics For over a decade, SG Analytics has been one of the leading global research & analytics firms with offices in USA, UK, Switzerland, and India, servicing scores of customers across the globe. We are the partner of choice for Fortune 500 companies across several sectors. We have been recognized as the “Best Employer” by the World HRD Congress in 2018. For further information, please visit our website:sganalytics.com Join the conversation This document makes descriptive reference to trademarks that may be owned by others. The use of such trademarks herein is not an assertion of ownership of such trademarks by SG Analytics (SGA) and is not intended to represent or imply the existence of an association between SGA and the lawful owners of such trademarks. Information regarding third-party products, services, and organizations was obtained from publicly available sources, and SGA cannot confirm the accuracy or reliability of such sources or information. Its inclusion does not imply an endorsement by or of any third party. SGA Whitepaper | May 20209 www.sganalytics.com Copyright © 2020 SG Analytics Pvt. Ltd. 9

More Related